OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2021-12-31-accounts

Charity number: 1166985

THE LIVER GROUP CHARITY CIO

UNAUDITED ANNUAL REPORT AND ACCOUNTS

YEAR ENDED 31 DECEMBER 2021

LUBBOCK FINE LLP Chartered Accountants Paternoster House 65 St Paul's Churchyard London EC4M 8AB

THE LIVER GROUP CHARITY CIO

CONTENTS

Page
Reference and Administrative Details of the Charity, its Trustees and Advisers 1
Trustees' Report 2 - 5
Chairman's Statement 6
Independent Examiner's Report 7
Statement of Financial Activities 8
Balance Sheet 9
Notes to the Financial Statements 10 - 17
The following pages do not form part of the statutory financial statements:
Donations to the 'Liver for Life' appeal 18
Scientific publications and presentations 19

THE LIVER GROUP CHARITY CIO

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2021

Trustees Dr David Holbrook (Chairman)
Mary Collier
Susan Eggleton
Dr Martin Giles
Kay Glendinning MBE
Professor Clare Selden
Charity registered
number
1166985
Principal office
C/O Institute for Liver and Digestive Health
Royal Free Hospital Campus - University College Medical School
Rowland Hill Street
Hampstead
NW3 2PF
Patron
Prof Sir Roger Penrose OM FRS
Accountants
Lubbock Fine LLP
Chartered Accountants & Statutory Auditors
Paternoster House
65 St Paul's Churchyard
London
EC4M 8AB

Page 1

THE LIVER GROUP CHARITY CIO

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2021

The Trustees present the annual report together with the financial statements of The Liver Group Charity CIO for the year ended 31 December 2021. The Trustees confirm that the Annual Report and financial statements of the Charity comply with the current statutory requirements, the requirements of the Charity’s governing document and provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Reference and administrative details

The Liver Group Charity CIO ("the Charity") is registered with the Charity Commission of England and Wales, under registration number 1166985. The Charity was registered on 6 May 2016 as a Charitable Incorporated Organisation, and as at 30 September 2016 took over the activities and assets of The Liver Group (registered charity number 1024533) which has subsequently been closed. The principal operating address is UCL Institute for Liver and Digestive Health, UCL - Royal Free Hospital Campus, University College Medical School, Upper Third Floor, Rowland Hill St, Hampstead, London NW3 2PF.

The Trustees who served in the year (including post year end appointments / resignations) were:

Dr David Holbrook (Chairman) Mary Collier Susan Eggleton Dr Martin Giles Kay Glendinning MBE Prof Clare Selden

Prof Sir Roger Penrose OM FRS — Patron

Structure, governance and management

The Board of Management comprised of six Trustees and one Patron during the year ended 31 December 2021. The members are able to draw on relevant board experience in board deliberations. The Board is collectively responsible for the competent management of the organisation in accordance with its objectives which are set out in the Trust Deed which is the Charity's governing document. The Board meets twice a year to monitor the organisation's strategy and activities.

If the need arose to appoint a new trustee the remaining Trustees would identify and appoint an appropriate person. The current Trustees are responsible for the induction of any new trustee which involves making them aware of the Trustees' responsibilities, the governing documents, administrative procedures and the history and philosophical approach of the Charity.

The Charity does not have any employees and its day to day activities and fundraising efforts are carried out by researchers from University College London, volunteers and trustees, under the supervision of one of the Trustees. The Trustees have agreed a position that should any profits arise from the intellectual property in the research being carried out by the team generally, and in conjunction with the various other parties involved in that work, the Charity would be entitled to a proportion of such amounts as per the Association of Medical Research Documentation (AMRC).

Page 2

THE LIVER GROUP CHARITY CIO

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Objectives and activities

The objects of the charity are:

  1. The relief of patients suffering from disease of the liver and genetic defects affecting the liver.

  2. The promotion of research into the causes and treatment of diseases of the liver on terms that the results of such research are published.

  3. Without prejudice to the generality of the foregoing to fund and support existing and future research into such matters at UCL Medical School (Liver Group) at the Royal Free Hospital or any other establishment into which such unit may be amalgamated and transferred in the future.

The principal activity of the Charity currently is the project being conducted to develop an artificial liver. The artificial liver project is being carried out with the funds raised for the continuing "Liver for Life" Appeal.

All the activities of the Charity were undertaken to further its purposes for the public benefit in line with the Charity's long-term objective of providing the relief of patients suffering from diseases of the liver and genetic defects affecting the liver, and promoting research into the causes and treatment of liver disease. The Charity has complied with section 17 of the Charities Act 2011 having due regard of the public benefit guidance published by the Commission.

Review of the period (including financial review)

The organisation remains funded mainly by donations. They are a mixture of individual, corporate and charitable trust donations. During the year external donations totalled £15,697 (2020: £32,749).

The majority of funds are spent on paying the cost of researchers, as well as the required consumables and equipment for the research to continue. As evidenced by the publications arising from the work, the Charity's current aim to develop a bio-artificial liver machine has moved forward from the medium scale to human scale, and now on to clinical scale, and towards readiness for a first-in-human trial.

The following period will see an advance to GMP manufacture, regulatory and ethics approval for a first in human trial. Each of these steps is associated with a considerable increase in research personnel, consumable and equipment expenditure. For 2021, expenditure totalled £134,090 (2020: £173,488). Except for such funds as the Trustees consider prudent to maintain for the purpose of management and administration of the Charity for the foreseeable future, all unrestricted funds are applied for the purposes of the 'Liver for Life" project and the general charitable objects of the Charity. The Trustees consider that £149,831 (2020: £93,931) of unrestricted reserves is more than sufficient to fund 6 months of current operations. During the period, the Charity recorded a deficit of £116,635 (2020: deficit of £137,167). The Charity's unrestricted fund is already committed to existing research.

As the bio-artificial liver project nears clinical scale and development for clinical trial, the costs are rapidly increasing necessitating considerable further fund-raising.

During 2017, the Trustees, on behalf of The Liver Group Charity CIO, entered into an agreement with Liver Health such that a proportion of any income from the sale of their drink product will be donated to The Liver Group Charity CIO. The Trustees felt that this would be a beneficial outcome for the charity if the product is successful. As well as proving a financial benefit, it would also raise awareness of the Charity itself and the risks of liver disease. This agreement is ongoing.

Page 3

THE LIVER GROUP CHARITY CIO

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Achievements and performance

The worldwide shortage of raw materials required in the biotech industry has severely delayed delivery of silicone-based tubing and plastics. The biggest and most lasting impact has been on the availability of cell culture plastics, chemicals and reagents, such as cell culture growth media. Unfortunately the manufacturers of these are the same suppliers of similar products used in vaccine production, so a legal edict from the Government (and Governments around the world) has made it such that any direct Covid-19-related order takes precedence over any other research and thus even on the waiting list the ETA keeps changing, and has in two cases risen from 8-12 weeks to more than 44 weeks. In May 2022 we have just received only two thirds of our ordered media supply, which has allowed us to restart at human scale, but still not the tubing required for the consumables. It was neither possible to foresee nor mitigate against these delays as the volumes and shelf lives of these products do not enable massive bulk ordering in advance as cold storage is also a problem on site.

Going concern

After making appropriate enquiries, the trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

Page 4

THE LIVER GROUP CHARITY CIO

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2021

Risk management

The Trustees confirm that there are ongoing processes for identifying, evaluating and managing significant risks faced by the organisation.

At the time of preparing these financial statements, the Covid pandemic was ongoing. Whilst the full impact on the charity’s finances and operations will not be known with certainty for some time, since early 2021 there has been a decrease in donation income and delays to the ongoing laboratory work. The trustees are monitoring the situation and taking the necessary steps to mitigate against any adverse impacts of Covid.

Plans for future periods

The Charity aims to continue its medical research goals, at a pace commensurate with funding opportunities. With appropriate funding, it sees the bio-artificial liver machine project reach the clinical trial assessment within five years.

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' Report and the financial statement in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Trustees and signed on their behalf by:

Dr Martin Giles (Trustee) Date: 13 October 2022

Page 5

THE LIVER GROUP CHARITY CIO

CHAIRMAN'S STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2021

The chairman presents his statement for the Year.

It has been another year hampered by the pandemic, with staff shortages, lab closures, supply issues, and difficulties in fundraising all to contend with. Despite these strictures, Clare and the team have made great progress on a number of important fronts.

Firstly, UCL has finally accepted our terms and conditions enabling them to regard us as undertaking sponsored research. This is still to be formalised, however this would mean a lower cost to the Charity. I would like to thank Mary Collier for her help on contractual maters in relation to this issue.

Secondly, and despite the difficulties, we still managed to raise over £15,000 during the year, including a £7,600 donation from the Christmas letter appeal.

On the overall financial front, it means we come out of this year with just over £432,000 in the bank. Fundraising is always difficult at the best of times and the challenge going forward is to ensure we have enough funding to take the HepatiCan ™ project to the point where commercial funding takes over.

On the technical front there have been some significant achievements since my last statement, including precompliance testing of the workstation for electrical safety and emissions; finalising of tubing mapping; usability study and ISO standard draft report; interfacing HepatiCan ™ with apheresis equipment; improving software on graphical interface; and starting work on improving and automating smaller scale chamber mimic of disposable chamber to overcome current raw material availability issues.

There is a full plan of activities for the next 12 months also in place which we shall report on next year. All in all Clare and her team deserve much thanks for their endeavours and achievements in a difficult environment.

On the governance front the board has sought to manage its finances more prudently in terms of bank accounts and financial controls and has adopted a more formal approach to risk audit and management. I would like to thank Martin Giles in particular for his help in these matters.

In terms of the research team, we have had one Liver Group Charity funded student Maooz Awan complete, submit and had viva for a PhD.

In summary, much has been achieved in difficult circumstances and I would like to thank all involved – in particular Clare and Elizaveta, our tireless administrator, – for keeping the wheels on in such a professional manner.

Dr David Holbrook Chairman

13 October 2022 Date:

Page 6

THE LIVER GROUP CHARITY CIO

INDEPENDENT EXAMINER'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2021

Independent Examiner's Report to the Trustees of The Liver Group Charity CIO ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the Year ended 31 December 2021.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Lee Facey

Lubbock Fine LLP Chartered Accountants & Statutory Auditors Paternoster House 65 St Paul's Churchyard London EC4M 8AB Date: 14 October 2022

Page 7

THE LIVER GROUP CHARITY CIO

STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2021

Note
Income from:
Donations and legacies
2
Investments
3
Total income
Expenditure on:
Charitable activities
4
Total expenditure
Net movement in funds after recognised gains
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward
Unrestricted
funds
2021
£
15,697
1,758
17,455
134,090
134,090
(116,635)
467,991
(116,635)
351,356
Total
funds
2021
£
15,697
1,758
17,455
134,090
134,090
(116,635)
467,991
(116,635)
351,356
Total
funds
2020
£
32,749
3,572
36,321
173,488
173,488
(137,167)
605,158
(137,167)
467,991

The Statement of Financial Activities includes all gains and losses recognised in the Year.

The notes on pages 10 to 17 form part of these financial statements.

Page 8

THE LIVER GROUP CHARITY CIO

BALANCE SHEET

AS AT 31 DECEMBER 2021

Note
Current assets
Debtors
6
Cash at bank and in hand
Creditors: amounts falling due within one
year
7
Net current assets
Creditors: amounts falling due after more
than one year
8
Net assets
Total net assets
Charity funds
Restricted funds
9
Unrestricted funds
9
Total funds
2021
£
3,333
432,867
436,200
(65,758)
2021
£
370,442
(19,086)
351,356
351,356
-
351,356
351,356
2020
£
2,462
561,859
564,321
(96,330)
2020
£
467,991
-
467,991
467,991
-
467,991
467,991

The figures shown in brackets above represent amounts payable by the Charity as at 31 December.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Dr David Holbrook Chairman

13 October 2022 Date:

The notes on pages 10 to 17 form part of these financial statements.

Page 9

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

1. Accounting policies (continued)

1.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

1.6 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered.

1.7 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.8 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

Trade and other creditors are recognised at the settlement amount after any trade discounts received. Accruals are value based on the estimated amount to be paid.

1.9 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.11 Donated goods and services

The Charity does not value donated services in the accounts. Services that are received, such as volunteers' time and the use of the laboratory space at University College London are either deemed not to be material or too onerous to value for a charity of this size.

Page 11

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

2. Income from donations and legacies

Donations

Donations
Grants
3.
Investment income
Bank Interest
Bank Interest
Unrestricted
funds
2021
£
15,697
Unrestricted
funds
2020
£
8,789
-
8,789

Restricted
funds
2021
£
-
Restricted
funds
2020
£
3,960
20,000
23,960
Unrestricted
funds
2021
£
1,758
Unrestricted
funds
2020
£
3,572
Total
funds
2021
£
15,697
Total
funds
2020
£
12,749
20,000
32,749
Total
funds
2021
£
1,758
Total
funds
2020
£
3,572

4. Analysis of expenditure by activities

Activities
undertaken Support Total
directly costs funds
2021 2021 2021
£ £ £
Charitable costs 131,156 2,934 134,090

Page 12

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

4. Analysis of expenditure by activities (continued)

Charitable costs
Analysis of direct costs
Activities
undertaken
directly
2020
£
170,595
Support
costs
2020
£
2,893
Total
funds
2020
£
173,488
Researchers (costs paid to UCL)
Researchers (costs paid to UCL)
Analysis of support costs
Accountancy fee
Independent examination fees (governance)
Bank charges
Activities
2021
£
131,156
Activities
2020
£
170,595
Activities
2021
£
1,350
750
834
2,934
Total
funds
2021
£
131,156
Total
funds
2020
£
170,595
Total
funds
2021
£
1,350
750
834
2,934

Page 13

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

4. Analysis of expenditure by activities (continued)

Analysis of support costs (continued)

Accountancy fee
Independent examination fees (governance)
Bank charges
Activities
2020
£
1,650
750
493
2,893
Total
funds
2020
£
1,650
750
493
2,893

5. Staff costs

The Charity had no employees during the period but supported the costs of researchers who are themselves employed by University College London.

The average monthly number of UCL employees supported by The Liver Group Charity CIO during the period was 4. At the period-end there were 4 employees of UCL working on The Liver Group Charity CIO funded research.

During the period, a number of volunteers gave their time to assist the Charity. No remuneration, other than travel expenses to and from the place of work, were paid to them and the Charity thanks them for their generosity.

From 1 May 2018 to 30 April 2020, UCL staff salaries were covered by other external academic grant funding to the UCL research project (external to charity fundraising/funding).

The Trustees did not receive any renumeration, benefits in kind and reimbursement of expenses (2020: £nil).

6. Debtors

Due within one year
Accrued income
2021
£
3,333
3,333
2020
£
2,462
2,462

Page 14

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

7. Creditors: Amounts falling due within one year

Amounts due to UCL
Accruals
2021
£
63,658
2,100
65,758
2020
£
94,230
2,100
96,330

8. Creditors: Amounts falling due after more than one year

2021 2020
£ £
Amounts due to UCL 19,086 -
9. Statement of funds
Statement of funds - current Year
Balance at
Balance at 1 31
January December
2021 Income Expenditure 2021
£ £ £ £
General funds
General Funds 467,991 17,455 (134,090) 351,356

Page 15

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

9. Statement of funds (continued)

Statement of funds - prior Year

Unrestricted funds
General Funds
Restricted funds
The Garfield Weston Foundation
The Robert Luff Foundation
Storyline Fund
Total of funds
Balance at
1 January
2020
£
557,324
47,834
-
-
47,834
605,158
Income
£
12,361
-
20,000
3,960
23,960
36,321
Expenditure
£
(101,694)
(47,834)
(20,000)
(3,960)
(71,794)
(173,488)
Balance at
31
December
2020
£
467,991
-
-
-
-
467,991

The Garfield Weston Foundation grant was received to fund key equipment required to enable cryopreservation of biomass for a bioartificial liver machine developed to treat patients with severe acute liver failure. The fund is applied in accordance with the restrictions imposed.

The Robert Luff Foundation grant was received to fund research to carry out testing using a bioartificial livery system and sterile human plasma to provide treatment to "buy time" for a patient's own liver to recover. The fund is applied in accordance with the restrictions imposed.

The Storyline Fund was donated specifically for the purpose of creating the "Storyline" pitch, slide deck and brochure content.

10. Analysis of net assets between funds

Analysis of net assets between funds - current year

Current assets
Creditors due within one year
Creditors due in more than one year
Total
Unrestricted
funds
2021
£
436,200
(65,758)
(19,086)
351,356
Total
funds
2021
£
436,200
(65,758)
(19,086)
351,356

Page 16

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

10. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

Current assets
Creditors due within one year
Total
Unrestricted
funds
2020
£
564,321
(96,330)
467,991
Total
funds
2020
£
564,321
(96,330)
467,991

11. Related party transactions

Donations from trustees totalled £nil (2020 - £4,060) during the year.

There were no other related party transactions during the current year or prior year.

Page 17

����������������������������

�����������������������������������������

������������������������������������������������������������������������������

����������� �����������

������������������������������������� �������� ���������� �������� �������������� ������������������������������������ �����������������������������

������������ ���������������� �������������������������������������� ������������������������������������������ ������

��������

�������� ���������� ������������������������������������ ���������� ���� ������������� ������������������������� ���������������� ��������� ��������������� ��������������� ������������������ ���������������� ������������������������ ����������� ���������

������������������������������������� ������������� �����������

������������� ��������� ��������������������������� ��������������������������������������� ������������������������������������� ������������������������������������������

������������������ �����������������

��������������������� ������������������

���������

������������������������������� �������� �������������������������� ���������� ����������������������������

�������������������������� ��������������������������������� ����� �������������������������������� ���������� �������������������������

�������������������������������������

�������� ������������������������������� ������������������������������������� ��������� ���������������������������� �����������������

�����������������

����������������� �������������������� ������������������ ����������������� �������� ���������� ���������������� ����������������

���������������������� ������������������������������� ��������� �������������� ����������� ����������������������������������� �������������� �������������������������������������� �������������������������������

��������� ������ ������������������������������ ��������������

������������������������������������ ��������������� �������� ��������������������������������� ����������� ����

����������������� �������� ������������������������������������� ���������� ����������

������������������ ���������������������������� ��������������������������� ���������������������� ������������������������������� �������������������������������������������

������� ���������� �������������� ������������������������������������� �������������� ���������� ������������������������������� ����������������� ������������� �������������������� ������������������������� ������������������

����������������������������������������

��������������������� ������������������������ ������������������������������� �����������������������������������������

������������� ��������������������������� ���������������������������� ��������������������������������������� ������������������������ ��������������������������������������������� �������������������� ���������������������������� ���������������������������� �������������������������� �������������� ���������������������� ����������������� ��������������������������� ������������������������������� ������������������������������ ������������������������� �������������������� ������������������������������ ��������������������������� �������������������������������������������� ������ ����������������������������� ����������������������������������� ���������������������������� �������������������� ������������������������������������������ ����������������������������������� ������������������������������� ������������������������������������� ������������������ ������������������������� ���������������������� �������������������������� �������������� ���������������������� ��������������������������� ������������������������������������� ����������������������������������� ���������������������������������� ������������������������������������� �������������������������� ��������� �������������������������������� ������������

��������� ��������������������������

��������� ������������ �������������� ������������������������������ ����������������������������������������

������������������������������

����������������

We would also like to thank those who have donated anonymously.

Page 18

����������������������������

���������������������������������������������������������������������

����������������������������������������������������������������������������������������������� ����

������������������������������������������������������������������������������������������ �����������������

������������������ ��������������

Page 19